Abstract:Biologically active proteins/regions without stable structure (i.e., intrinsically disordered proteins and regions (IDPs and IDRs)) are commonly found in all proteomes. They have a unique functional repertoire that complements the functionalities of ordered proteins and domains. IDPs/IDRs are multifunctional promiscuous binders capable of folding at interaction with specific binding partners on a template- or context-dependent manner, many of which undergo liquid-liquid phase separation, leading to the formation of membrane-less organelles and biomolecular condensates. Many of them are frequently related to the pathogenesis of various human diseases. All this defines IDPs/IDRs as attractive targets for the development of novel drugs. However, their lack of unique structures, multifunctionality, binding promiscuity, and involvement in unusual modes of action preclude direct use of traditional structure-based drug design approaches for targeting IDPs/IDRs, and make disorder-based drug discovery for these "protein clouds" challenging. Despite all these complexities there is continuing progress in the design of small molecules affecting IDPs/IDRs. This article describes the major structural features of IDPs/IDRs and the peculiarities of the disorder-based functionality. It also discusses the roles of IDPs/IDRs in various pathologies, and shows why the approaches elaborated for finding drugs targeting ordered proteins cannot be directly used for the intrinsic disorder-based drug design, and introduces some novel methodologies suitable for these purposes. Finally, it emphasizes that regardless of their multifunctionality, binding promiscuity, lack of unique structures, and highly dynamic nature, "protein clouds" are principally druggable. Significance Statement Intrinsically disordered proteins and regions are highly abundant in nature, have multiple important biological functions, are commonly involved in the pathogenesis of a multitude of human diseases, and are therefore considered as very attractive drug targets. Although dealing with these unstructured multifunctional protein/regions is a challenging task, multiple innovative approaches have been designed to target them by small molecules.

Proteasome activation: A novel strategy for targeting undruggable intrinsically disordered proteins

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Rational Drug Design Targeting Intrinsically Disordered Proteins

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Targeting intrinsically disordered proteins at the edge of chaos

Degradation of intrinsically disordered proteins using proteolysis targeting nanobody conjugate

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Structure-Based Inhibitor Design for the Intrinsically Disordered Protein C-Myc

Computational Strategy for Intrinsically Disordered Protein Ligand Design Leads to the Discovery of P53 Transactivation Domain I Binding Compounds That Activate the P53 Pathway

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials

Proteasome dysregulation in human cancer: implications for clinical therapies

Targeted protein degradation in drug development: Recent advances and future challenges

Binding Cavities and Druggability of Intrinsically Disordered Proteins.

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation: mechanisms, strategies and application

Novel approaches to targeted protein degradation technologies in drug discovery

Drug design targeting active posttranslational modification protein isoforms

How to drug a cloud? Targeting intrinsically disordered proteins

Ubiquitin‐Independent Degradation: An Emerging PROTAC Approach?